Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.55 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13752132 | 0.74 | IDH1 (0.43) | RIPK1 | |
| SCHEMBL19471106 | 0.73 | RIPK1 (0.48) | RIPK1BRD4TSHRKMT2AALDH1A1 | |
| SCHEMBL17870950 | 0.73 | RIPK1 (0.48) | RIPK1BRD4TSHRKMT2AALDH1A1 | |
| SCHEMBL24774469 | 0.73 | RIPK1 (0.40) | RIPK1ALDH1A1ATMPDE5A | |
| SCHEMBL6073850 | 0.73 | RIPK1 (0.51) | RIPK1BRD4TSHRKMT2AALDH1A1 | |
| SCHEMBL17870934 | 0.72 | RIPK1 (1.00) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19471130 | 0.72 | RIPK1 (1.00) | RIPK1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5144827 | 0.71 | RIPK1 (0.43) | RIPK1BRD4TSHRKMT2AALDH1A1 | |
| SCHEMBL17870957 | 0.71 | RIPK1 (0.47) | RIPK1BRD4TSHRKMT2AALDH1A1 | |
| SCHEMBL10061592 | 0.71 | RIPK1 (0.61) | RIPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | RIPK1 326/4885BRD4 167/4885TSHR 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.